NeuroOne's submission of its RF ablation system for FDA 510(k) clearance marks a significant step forward in its pursuit of providing advanced treatment options for patients. If granted clearance, this technology could offer healthcare professionals a valuable tool in treating various medical conditions, potentially improving patient care and quality of life. Fast Five hosts Sean Whooley and Danielle Kirsh explain how the technology works. 

Neuronetics' recent FDA clearance for its OCD motor threshold (MT) cap technology for NeuroStar advanced therapy for mental health reinforces the importance of continued research and development in the field of mental health. Whooley details the transcranial magnetic stimulation and how optimistic executives at the company are.

The unveiling of Stevanato Group's on-body drug delivery device represents a significant advancement in medication administration for the company. With its programmable micro-precision basal doses and full-content basal injections, Vertiva can cover a range of therapies. Kirsh and Whooley discuss how the company designed the device and what applications it can be used for.

Dexcom's recent study highlighting the impact of diabetes on mental health sheds light on an important aspect of diabetes management. This study emphasizes the need for a comprehensive approach to diabetes care, considering both physical and mental well-being. Whooley provides the data from the study and Dexcom's response. 

Medtronic's warning regarding potential cardioversion damage associated with certain Vanta neurostimulators serves as an important safety update for healthcare professionals and patients. The Fast Five hosts explain the reason behind the recall and the mitigation steps Medtronic is taking. 

Check out the show notes at MassDevice.com/podcast.

Ver todos los episodios